Insider Selling: Teleflex Incorporated (TFX) Director Sells $1,006,512.00 in Stock

Teleflex Incorporated (NYSE:TFX) Director Stephen K. M.D. Klasko sold 5,200 shares of the company’s stock in a transaction dated Monday, May 15th. The stock was sold at an average price of $193.56, for a total value of $1,006,512.00. Following the completion of the sale, the director now directly owns 12,880 shares of the company’s stock, valued at approximately $2,493,052.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Teleflex Incorporated (NYSE:TFX) opened at 194.50 on Friday. Teleflex Incorporated has a 1-year low of $136.53 and a 1-year high of $211.22. The company has a 50 day moving average price of $198.01 and a 200 day moving average price of $175.61. The firm has a market cap of $8.75 billion, a PE ratio of 40.37 and a beta of 0.93.

Teleflex (NYSE:TFX) last issued its quarterly earnings results on Thursday, May 4th. The medical technology company reported $1.80 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.69 by $0.11. The company had revenue of $487.90 million for the quarter, compared to the consensus estimate of $472.81 million. Teleflex had a return on equity of 15.66% and a net margin of 15.09%. The firm’s revenue was up 14.8% compared to the same quarter last year. During the same period last year, the business posted $1.52 earnings per share. On average, equities research analysts forecast that Teleflex Incorporated will post $8.16 earnings per share for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Thursday, June 15th. Stockholders of record on Monday, May 15th will be given a $0.34 dividend. This represents a $1.36 annualized dividend and a dividend yield of 0.70%. The ex-dividend date is Thursday, May 11th. Teleflex’s dividend payout ratio is currently 23.49%.

WARNING: This news story was first posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright legislation. The correct version of this news story can be accessed at https://www.chaffeybreeze.com/2017/05/19/insider-selling-teleflex-incorporated-tfx-director-sells-1006512-00-in-stock.html.

Large investors have recently modified their holdings of the stock. Great West Life Assurance Co. Can increased its stake in shares of Teleflex by 1.6% in the third quarter. Great West Life Assurance Co. Can now owns 26,029 shares of the medical technology company’s stock valued at $4,372,000 after buying an additional 422 shares in the last quarter. Rothschild Asset Management Inc. increased its stake in shares of Teleflex by 14.9% in the third quarter. Rothschild Asset Management Inc. now owns 2,884 shares of the medical technology company’s stock valued at $485,000 after buying an additional 373 shares in the last quarter. Capital Fund Management S.A. increased its stake in Teleflex by 2,726.0% in the third quarter. Capital Fund Management S.A. now owns 36,258 shares of the medical technology company’s stock worth $6,093,000 after buying an additional 34,975 shares during the period. Quantbot Technologies LP purchased a new stake in Teleflex during the third quarter worth $2,749,000. Finally, LMR Partners LLP purchased a new stake in Teleflex during the third quarter worth $6,913,000. 93.02% of the stock is currently owned by institutional investors.

Several equities research analysts have recently weighed in on the company. Needham & Company LLC reaffirmed a “buy” rating and issued a $224.00 target price on shares of Teleflex in a research report on Friday, May 5th. Deutsche Bank AG upped their target price on Teleflex from $213.00 to $220.00 and gave the stock a “buy” rating in a research report on Monday, May 8th. Zacks Investment Research raised Teleflex from a “hold” rating to a “buy” rating and set a $217.00 target price for the company in a research report on Tuesday, March 14th. Jefferies Group LLC reaffirmed a “hold” rating on shares of Teleflex in a research report on Monday, March 27th. Finally, Barclays PLC reaffirmed a “buy” rating and issued a $205.00 target price on shares of Teleflex in a research report on Wednesday, March 1st. Two analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $208.00.

About Teleflex

Teleflex Incorporated is a provider of medical technology products. The Company designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for diagnostic and therapeutic procedures in critical care and surgical applications. The Company operates through six segments: Vascular North America; Anesthesia North America; Surgical North America; Europe, the Middle East and Africa (EMEA); Asia, and Original Equipment Manufacturer (OEM).

5 Day Chart for NYSE:TFX

Receive News & Ratings for Teleflex Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply